Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/47721
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlkan, Ali-
dc.contributor.authorGuc, Zeynep Gulsum-
dc.contributor.authorGurbuz, Mustafa-
dc.contributor.authorozgun, Guliz-
dc.contributor.authorDegirmencioglu, Serkan-
dc.contributor.authorDogan, Mutlu-
dc.contributor.authorUrun, Yuksel-
dc.date.accessioned2023-01-09T21:29:46Z-
dc.date.available2023-01-09T21:29:46Z-
dc.date.issued2021-
dc.identifier.issn1875-6867-
dc.identifier.issn1875-6859-
dc.identifier.urihttps://doi.org/10.31083/jomh.2021.041-
dc.descriptionTanriverdi, Ozgur/0000-0002-0598-7284; Oksuzoglu, Berna/0000-0002-2756-8646; Akin Telli, Tugba/0000-0001-6535-6030; Turkkan, Gorkem/0000-0002-9084-2599; Bilgin, Burak/0000-0003-1717-8246; Gurbuz, Mustafa/0000-0001-7680-4142; Kostek, Osman/0000-0002-1901-5603; Guc, Zeynep Gulsum/0000-0001-8960-2208; Yasar, Hatime/0000-0002-0545-1383en_US
dc.description.abstractIntroduction: The efficacy and tolerability of Enzalutamide and Abiraterone Acetate have been reported in elderly patients with metastatic castration resistant prostate cancer (mCRPC). However, there is no randomized study directly comparing antitumor effects between these 2 agents in geriatric patients. We aimed to evaluate the efficacy of Enzalutamide (ENZA) and Abiraterone Acetate (AA) as a first-line treatment of mCRPC in elderly patients. Materials and methods: The geriatric patients (>= 75 years of age) with a diagnosis of mCRPC and treated with first-line ENZA or AA were included. The impacts of clinical parameters and treatment modalities on overall survival (mOS) were analyzed retrospectively and Cox regression analysis was performed. Results: One hundred thirty-four mCRPC patients (77 in AA, 57 in ENZA), with a median age of 81 (75-93) were analyzed. The patient and disease characteristics were similar between arms. While there were more grade 1-2 toxicities in AA arm (45.5% vs 17.5%, P = 0.001), the discontinuation due to toxicity was similar between groups (8.5% vs 5.9%, P = 0.81). The mOS was 18.0 months (95% CI, 15.2-20.7) in AA, and 20.0 months (95% CI, 4.4-35.5) in ENZA arm (P = 0.47). In multivariate analysis, high Gleason score (>= 8) (HR: 2.0 (95% CI, 1.1-3.4), P = 0.009) and high initial PSA values (>= 100 ng/mL) (HR: 2.6 (95% CI, 1.5-4.8), P = 0.001) were poor prognostic factors. The choice of AA vs ENZA was insignificant as a predictor of OS (HR: 0.87 (95% CI, 0.48-1.56), P = 0.65). Conclusion: In the first-line treatment of mCRPC in elderly (>= 75) patients, AA and ENZA showed similar results in terms of mPFS and mOS. The clinical impacts of second-generation androgen receptor pathway inhibitors in the elderly population should be tested in prospective randomized studies.en_US
dc.language.isoenen_US
dc.publisherMre Pressen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMetastatic Castration-Resistant Prostate Canceren_US
dc.subjectEnzalutamideen_US
dc.subjectAbiraterone Acetateen_US
dc.subjectElderlyen_US
dc.titleEnzalutamide Versus Abiraterone Acetate as First-Line Treatment of Castration Resistant Metastatic Prostate Cancer in Geriatric (≥75) Patientsen_US
dc.typeArticleen_US
dc.identifier.volume17en_US
dc.identifier.issue4en_US
dc.identifier.startpage128en_US
dc.identifier.endpage134en_US
dc.departmentPamukkale Universityen_US
dc.authoridTanriverdi, Ozgur/0000-0002-0598-7284-
dc.authoridOksuzoglu, Berna/0000-0002-2756-8646-
dc.authoridAkin Telli, Tugba/0000-0001-6535-6030-
dc.authoridTurkkan, Gorkem/0000-0002-9084-2599-
dc.authoridBilgin, Burak/0000-0003-1717-8246-
dc.authoridGurbuz, Mustafa/0000-0001-7680-4142-
dc.authoridYasar, Hatime/0000-0002-0545-1383-
dc.identifier.doi10.31083/jomh.2021.041-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorwosidArslan, Cagatay/I-1932-2016-
dc.authorwosidÖksüzoğlu Çakmak, Ömür Berna/Hkn-6428-2023-
dc.authorwosidGüç, Zeynep/Agx-1276-2022-
dc.authorwosidCicin, Irfan/Aaq-5575-2020-
dc.authorwosidAlkan, Ali/P-3554-2019-
dc.authorwosidYaşar, Hatime Arzu/Hgc-5631-2022-
dc.authorwosidErturk, Ismail/B-4317-2019-
dc.identifier.scopus2-s2.0-85116774416en_US
dc.identifier.scopus2-s2.0-85116774416-
dc.identifier.wosWOS:000699924300001-
dc.identifier.scopusqualityQ3-
dc.description.woscitationindexScience Citation Index Expanded - Social Science Citation Index-
dc.identifier.wosqualityQ4-
item.languageiso639-1en-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.